View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 24, 2019updated 20 Jul 2022 5:44am

Trial to test insomnia drug for alcohol use disorder

Researchers at The Florey Institute of Neuroscience and Mental Health and St Vincent’s Hospital in Australia have commenced a clinical trial of Belsomra (suvorexant) for the prevention of alcohol intake and alcohol use disorder relapse.

Researchers at The Florey Institute of Neuroscience and Mental Health and St Vincent’s Hospital in Australia have commenced a clinical trial of Belsomra (suvorexant) for the prevention of alcohol intake and alcohol use disorder relapse.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Belsomra is manufactured by MSD . It is currently used to treat insomnia in the country.

The new double-blinded trial will assess the drug in 128 patients with co-occurring insomnia and alcohol use disorder.

The Florey Institute professor Andrew Lawrence said: “Over 155,000 Australians are hospitalised each year from alcohol use disorder. Yet despite the significant social and economic burden of this disease, no new treatments have been approved in Australia in over two decades.”

For more than 15 years, Lawrence and his team have been exploring the brain mechanisms associated with alcohol use disorder. Researchers discovered that the orexin peptide system in the brain drives alcohol use relapse.

They believe that Belsomra could help in the integrated treatment of alcohol use disorder and co-occurring sleep disorder.

The drug works by inhibiting the binding of orexin in the brain parts related to addiction. It also acts on the amygdala region of the brain linked to mood disorders such as depression and anxiety.

Lawrence added: “The orexin system demonstrates just how complicated addiction can be. We know that chronic intake of alcohol greatly disrupts sleep and wake patterns which, in turn, can drive the brain to further seek and consume alcohol.”

During the clinical trial, researchers will monitor sleep measures, along with alcohol withdrawal symptoms and ongoing alcohol use.

Participants will receive Belsomra or placebo daily for seven to ten days in the hospital, followed by treatment and monitoring for up to six months.

Based on the trial results, researchers hope to study the drug in larger populations and other types of substance abuse.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena